Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

501 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Low-Dose Colchicine on Serum High-Sensitivity C-Reactive Protein Level in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus and Enhanced Inflammatory Response Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose-Finding Study.
Miwa Y, Mutoh A, Morimoto T, Ikehara Y, Yasu T, Koba S, Ako J, Higashi Y, Kajikawa M, Uehara H, Ishikawa K, Sakuma I, Tomiyama H, Node K, Kumagai Y, Ueda S. Miwa Y, et al. Among authors: sakuma i. Biomed Hub. 2022 Dec 5;7(3):156-164. doi: 10.1159/000527411. eCollection 2022 Sep-Dec. Biomed Hub. 2022. PMID: 36643381 Free PMC article.
Study protocol of the PROUD48 study comparing the effects of pemafibrate and omega-3 fatty acid ethyl esters on ApoB-48 in statin-treated patients with dyslipidaemia: a prospective, multicentre, open-label, randomised, parallel group trial in Japan.
Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S, Sakurai M. Takeda Y, et al. Among authors: sakuma i. BMJ Open. 2022 Nov 14;12(11):e061360. doi: 10.1136/bmjopen-2022-061360. BMJ Open. 2022. PMID: 36375977 Free PMC article.
The effects of pemafibrate and omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study).
Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S, Sakurai M. Takeda Y, et al. Among authors: sakuma i. Front Cardiovasc Med. 2023 Jan 25;10:1094100. doi: 10.3389/fcvm.2023.1094100. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 36760560 Free PMC article.
Corrigendum: The effects of pemafibrate and Omega-3 fatty acid ethyl on apoB-48 in dyslipidemic patients treated with statin: A prospective, multicenter, open-label, randomized, parallel group trial in Japan (PROUD48 study).
Takeda Y, Sakuma I, Hiramitsu S, Okada M, Ueda S, Sakurai M. Takeda Y, et al. Among authors: sakuma i. Front Cardiovasc Med. 2023 Mar 16;10:1172664. doi: 10.3389/fcvm.2023.1172664. eCollection 2023. Front Cardiovasc Med. 2023. PMID: 37008309 Free PMC article.
Residual Coronary Risk Factors Associated With Long-Term Clinical Outcomes in Patients With Coronary Artery Disease Treated With High- vs. Low-Dose Statin Therapy　- REAL-CAD Substudy.
Higuma T, Akashi YJ, Fukumoto Y, Obara H, Kakuma T, Asaumi Y, Yasuda S, Sakuma I, Daida H, Shimokawa H, Kimura T, Iimuro S, Nagai R. Higuma T, et al. Among authors: sakuma i. Circ J. 2024 May 24;88(6):995-1003. doi: 10.1253/circj.CJ-23-0134. Epub 2023 Jul 21. Circ J. 2024. PMID: 37482412 Free article.
DAPagliflozin for the attenuation of albuminuria in Patients with hEaRt failure and type 2 diabetes (DAPPER study): a multicentre, randomised, open-label, parallel-group, standard treatment-controlled trial.
Yoshihara F, Imazu M, Sakuma I, Hiroi Y, Hara H, Okazaki O, Ishiguro C, Izumi C, Noguchi T, Shiraiwa T, Nishioka N, Fujii K, Iwakura K, Tomonaga O, Kobayashi K, Takihata M, Yumoto K, Takase H, Himi T, Shimizu I, Murakami T, Wagatsuma K, Sato K, Hiramatsu T, Akabame S, Hata S, Asakura M, Kawabata T, Omae K, Ito S, Kitakaze M; DAPPER Investigators. Yoshihara F, et al. Among authors: sakuma i. EClinicalMedicine. 2023 Nov 27;66:102334. doi: 10.1016/j.eclinm.2023.102334. eCollection 2023 Dec. EClinicalMedicine. 2023. PMID: 38192595 Free PMC article.
Plasma ANGPTL8 Levels and Risk for Secondary Cardiovascular Events in Japanese Patients With Stable Coronary Artery Disease Receiving Statin Therapy.
Morinaga J, Kashiwabara K, Torigoe D, Okadome Y, Aizawa K, Uemura K, Kurashima A, Matsunaga E, Fukami H, Horiguchi H, Sato M, Sugizaki T, Miyata K, Kadomatsu T, Mukoyama M, Miyauchi K, Hokimoto S, Fukumoto Y, Hiro T, Hibi K, Nakagawa Y, Sakuma I, Ozaki Y, Iwata H, Iimuro S, Daida H, Shimokawa H, Kimura T, Matsuzaki M, Saito Y, Matsuyama Y, Nagai R, Oike Y. Morinaga J, et al. Among authors: sakuma i. Arterioscler Thromb Vasc Biol. 2023 Aug;43(8):1549-1559. doi: 10.1161/ATVBAHA.122.318880. Epub 2023 Jun 1. Arterioscler Thromb Vasc Biol. 2023. PMID: 37259862 Clinical Trial.
Differential prediction of high-sensitivity cardiac troponin-I, but not N-terminal pro-brain natriuretic peptide, in different pitavastatin doses on cardiovascular events in stable coronary artery disease.
Mitsutake Y, Ishii J, Fukumoto Y, Ito S, Kashiwabara K, Uemura K, Matsuyama Y, Sugiyama Y, Ozaki Y, Iimuro S, Iwata H, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Hokimoto S, Miyauchi K, Daida H, Shimokawa H, Saito Y, Kimura T, Matsuzaki M, Nagai R. Mitsutake Y, et al. Among authors: sakuma i. Int J Cardiol. 2023 Sep 15;387:131138. doi: 10.1016/j.ijcard.2023.131138. Epub 2023 Jun 22. Int J Cardiol. 2023. PMID: 37355235 Free article. Clinical Trial.
Association between Non-Lipid Residual Risk Factors and Cardiovascular Events in Patients with Stable Coronary Artery Disease Treated with Pitavastatin: An Observation from the REAL-CAD Study.
Kamiya K, Takei M, Nagai T, Miyoshi T, Ito H, Fukumoto Y, Obara H, Kakuma T, Sakuma I, Daida H, Iimuro S, Shimokawa H, Kimura T, Nagai R, Anzai T. Kamiya K, et al. Among authors: sakuma i. J Atheroscler Thromb. 2024 Jan 1;31(1):61-80. doi: 10.5551/jat.64304. Epub 2023 Aug 11. J Atheroscler Thromb. 2024. PMID: 37574272 Free PMC article.
501 results